Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LRDS popped today. Exciting! One I have been holding and expecting a move.
I am confused by the last sentence in the article: "Should similar findings be observed at 60 days, Emergency Use Authorization will be sought."
I thought we already submitted EAU based on reduced length of stay?
As a physician who has been Principle Investigator of a number of NIH and Industry-sponsored trials, this makes perfect sense and does nothing to change projections. Common sense dictates that a primary endpoint in a study is easy to measure when there are dramatic and clear-cut changes. If the changes are subtle (think Alzheimer's progression and drug studies), then it takes more patients to have statistical power to prove the drug works. Nothing to see here. Move on.
RLFTF Competition. Unfortunately for them, way behind the 8-ball. Haven't initiated human clinical trials yet. However, like Aviptadil, this drug may have ramifications regarding future virus therapies including the common cold.
Article link: https://www.globenewswire.com/news-release/2020/12/21/2148705/0/en/Novan-Engages-Catalent-to-Develop-Intranasal-Formulation-of-Berdazimer-Sodium-for-COVID-19-Program.html
For those with ADHD: Novan initiated in vitro assessments of its NITRICILâ„¢ platform against the novel SARS-CoV-2 coronavirus, targeting the reduction of viral burden in differentiated normal human bronchial epithelial cells. The studies were conducted at the Institute for Antiviral Research at Utah State University, and these results demonstrated the first instance of an antiviral effect from a nitric oxide-based medicine in a 3-D tissue model that has similar structure to the human airway epithelium. The results from the in vitro assessment of concentrations as low as 0.75 mg/mL demonstrated that berdazimer sodium reduced 90% of virus after repeat dosing, once daily.
The interesting part of the new strain of mutations in the UK is that they have discovered that it involves changes to the "Spike" protein, the part of the virus that binds to the cell. This mutation could potentially affect the recently developed vaccinations and ease of transmission between humans. They don't conclude that is the case without further study. As a physician with knowledge in the area, this could be very scary. It has always been a concern that by the time our vaccines are developed the virus will mutate to a point to where it may render them ineffective.
Great post! 100% agree. I would add something else. The more this flies under the radar, the greater the bump in price with significant positive FDA news. Those who have been investing in other COVID stocks seeking a "home run" will come on board with RLFTF quickly. The key is in the science behind the drug (peptide). It has an excellent safety record which is paramount to FDA approval. Preliminary study data suggests promising efficacy greater than anything out there. The drug targets cells that COVID and other viruses attack. The RLFTF continues to add pieces to the team to ensure rapid distribution, manufacturing, and those who know how to get a drug FDA approved. Regarding the latter, RLFTF's leadership is the most connected to the FDA I have ever seen in a drug company, much less a small one like this.
Of course, there is always the potential of a setback. It is the nature of getting drugs through the FDA. Nothing is a "slam-dunk." That being said, I like my chances here.
FYI am am a clinician and researcher including participating in NIH-sponsored trials on drugs for FDA approval. I am patient on this stock. I'm all in and very excited for my portfolio; but also for potential lives saved if the drug proves as capable as it seems.
100% agree
While much of what you said is true, market makers can and often do unscrupulous things for self benefit.
See:
https://www.investopedia.com/articles/financialcareers/06/mmakertricks.asp
The key is in the statistical analyses. 21 patients or 2 thousand patients matters less than a P-value <.001. Meaning it is greater than 1000 percent chance that the results are meaningful
That's exactly what I think will happen next
I approve of this message :)
I cringed when I discovered the source. Thanks for not pouring salt in my wounds...
Based on his web site, he has a mix of real news, but also posts Fake Twitter news. Moron has a disclaimer on his website. Really dumb idea.
In hindsight, Looks like he runs a "Spoof" site, so take it with a grain of salt. Was reposted multiple times by others is how I picked it up. My apologies for not verifying the source better before posting.
Relief Therapeutics Holding $RLFTF to be featured on Mad Money with Jim Cramer next week gaining nationwide exposure.
Thanks for the technical analysis. Good stuff!
I hope so. Opportunity to buy more shares. This is not a typical shady penny stock. Lots of meat on the bones on this one. As a physician who uses Peptides in my practice, has extensive ICU work history, and has done my due diligence on this therapy, I am as confident as I can be that this drug and stock have amazing potential. I rarely hold a penny stock long (In fact, I never do). They are penny stocks for a reason (risky and unproven). But every once in a while something happens that causes disruptive innovation. For a penny stock, this breaks the mold. Flippers do not know about or care about the science of the product. BTW, I don't blame them. Their knowledge and training is around patterned market behavior. It serves well as it eliminates emotional decision making.; a critical flaw if you are a day or swing trader. I will also share that I have knowledge in the investing world as well, as I day and swing trade myself. IMHO (strong opinion) this stock is the exception to the rule. I am a humble guy who rarely puts his neck out there in public for fear of the guillotine. In a rare exhibition, my neck is stretched as far as possible right now. I am all in on $RLFTF.
Completely agree
IMHO, most penny stocks and even large stocks that have a RS do so because the stock prices are faltering and or they want to remain in compliance. RLFTF would have a complete different reason if they were to do a RS. Their stock is about to sky rocket and this could give them an opportunity to get in compliance with NASDAQ and be viable to more investors.That being said, my guess is we will not see RLFTF consider a RS till their price rises. RS are not always a bad thing, but if it is a crappy stock with a negative future best to get out when a RS is announced.
Add me to one of those who liked your bullet summary. Great work!
Well stated
Well said!
I heard crying out my window. Suspect the neighbor shorted $RLFTF
I am new to this site. Yes, my first post on here.
Nicely said JB. It seems you and I have a similar philosophy on trading. I rarely speak out. I prefer to stay humble and in the shadows. I eliminate the noise and do my own research. I usually stick to bio stocks as I am a physician and researcher. I understand the field of medicine, FDA approval process, and can scrutinize peer reviewed medical articles. I also offer cutting edge treatments in my practice including the use of various peptide therapies. I have done my DD on RLF-100, and have consolidated more monies in this one stock than I ever have done with any one stock before. I am so impressed with early safety and efficacy of the drug I am all in. It helps that this peptide has been around for a long time and already has a great safety profile. Good luck to all who are holding shares.